HFpEF is likely the next @fda.gov approved indication for #tirzepatide and other incretins.
I guestimate 50% of Americans will have an FDA approved indication for one by 2028
#medsky #liversky
I guestimate 50% of Americans will have an FDA approved indication for one by 2028
#medsky #liversky
Reposted from
NEJM.org
In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: nej.md/4hRGaTY
#MedSky #EndoSky #CardioSky
#MedSky #EndoSky #CardioSky
Comments